Search
Close
Search
Advanced Search
Search Menu

Abstract

There is a large and increasing global burden of cardiovascular disease. Approximately 14 million individuals died of cardiovascular vasease in 1990, and this is projected to rise to about 25 million by 2020. In large part, this increase can be explained on the basis of major ongoing sociodemographic changes in developing countries, and associated effects on the numbers of individuals at risk and the levels of cardiovascular risk factors. Developing countries now experience a much greater burden of cardiovascular disease than do developed countries. In addition, developing countries are expected to experience the greatest rise in cardiovascular disease burden over the next few years. Cardiovascular disease prevention programmes designed and implemented primarily in developed countries have most likely averted much premature cardiovascular disease in those countries over the past few decades. However, cardiovascular disease prevention programmes designed for developed countries are unlikely to be directly transferable to developing countries. Reliable information to inform the design and implementation of cardiovascular disease prevention programmes, tailored to the socioeconomic circumstances of developing countries, is now required. Such programmes have great potential to impact on the current and projected global epidemic of cardiovascular disease.

Cardiovascular disease burden, global

References

[1]

Murray
C
, Lopez A. The Global Burden of Disease. Cambridge: Harvard University Press; 1996.

[2]

Murray
C
, Lopez A. Global patterns of cause of death and burden of disease in 1990, with projections to 2020. Investing in Health Research and Development. Report of the Ad Hoe Committee on Health Research Relating to Future Intervention Options. Geneva: World Health Organization; 1996.

[3]

Yao
C
, Wu Z, Wu Y. The changing pattern of cardiovascular diseases in China.
World Health Stat Q
.
1993
;
46
:
113
–118

[4]

World Bank. World Development Report: Investing in Health. New York: Oxford University Press; 1993.

[5]

World Health Organization. World Health Statistics Annual. Geneva: World Health Organization; 1995.

[6]

World Bank. World Development Report 1999/2000: Entering the 21 st Century. New York: Oxford University Press; 1999.

[7]

World Bank. World Urbanization Prospects: The 1999 Revision. New York: Oxford University Press; 1999.

[8]

Pearson
T
, Jamison D, Trejo-Gutierrez H. Cardiovascular Disease. New York: Oxford University Press; 1993.

[9]

Drewnowski
A
, Popkin B. The nutrition transition: new trends in the global diet.
Nutr Rev
.
1997
;
55
:
31
–43

[10]

Beckett
L
, Rosner B, Roche A, Guo S. Serial changes in blood pressure from adolescence into adulthood.
Am J Epidemiol
.
1992
;
135
:
1166
–1177

[11]

Van Rooyen
J
, Kruger H, Huisman H, et al. An epidemiological study of hypertension and its determinants in a population in transition: the THUSA study.
J Hum Hypertens
.
2000
;
14
:
779
–787

[12]

Hakeem
R
, Thomas J, Badruddin S. Urbanisation and coronary heart disease risk factors in South Asian children.
J Pak Med Assoc
.
2001
;
51
:
22
–28

[13]

Hakeem
R
, Thomas J, Badruddin S. Rural-urban differences in food and nutrient intake of Pakistani children.
J Pak Mcd Assoc
.
1999
;
49
:
288
–294

[14]

Taylor
R
, Jalaludin B, Levy S, Montaville B, Gee K, Sladden T. Prevalence of diabetes, hypertension and obesity at different levels of urbanisation in Vanuatu.
Med J Aust
.
1991
;
155
:
86
–90

[15]

Yach
D
, Bettcher D. Globalisation of tobacco industry influence and new global responses.
Tob Control
.
2000
;
9
:
206
–216

[16]

World Health Organization. Tobacco or Health: a Global Status Report. Geneva: World Health Organization; 1997.

[17]

The WHO Monica Project. Geographical variation in the major risk factors of coronary heart disease in men and women aged 35–64 years.

World Health Star Q
.
1988
;
41
:
115
–139

[18]

Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts.

Lancet
.
1995
;
346
:
1647
–1653

[19]

Eastern Stroke and Coronary Heart Disease Collaborative Research Group. Blood pressure, cholesterol and stroke in eastern Asia.

Lancet
.
1998
;
352
:
1801
–1807

[20]

Doll
R
, Peto R, Wheatley K, Gray R, Sutherland I. Mortality in relation to smoking: 40 years' observations on male British doctors.
BMJ
.
1994
;
309
:
901
–911

[21]

Chen
Z-M
, Xu Z, Collins R, Li W-X, Peto R. Early health effects of the emerging tobacco epidemic in China: A 16-year prospective study.
JAMA
.
1997
;
278
:
1500
–1504

[22]

Uemura
K
, Pisa Z. Trends in cardiovascular disease mortality in industrialised countries since 1950.
World Health Stat Q
.
1998
;
41
:
155
–168

[23]

Lopez
A
. Assessing the burden of mortality from cardiovascular disease.
World Health Stat Q
.
1993
;
46
:
91
–96

[24]

Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients.

BMJ
.
1994
;
308
:
81
–106

[25]

Collins
R
, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease.
Br Med Bull
.
1994
;
50
:
272
–298

[26]

ISIS Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.

Lancet
.
1988
;:
349
–360

[27]

Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists and other blood pressure lowering drugs: results of prospectively designed overviews of randomised trials.

Lancet
.
2000
;
356
:
1955
–1964

[28]

Ad Hoc Committee on Health Research Relating to Future Intervention Options. Investing in Health Research and Development. Geneva: World Health Organization; 1996.

[29]

Institute of Medicine Board on International Health. Control of Cardiovascular Diseases in Developing Countries. Washington, DC: National Academy Press; 1997.

[30]

Wu
Z
, Yao C, Zhao D, et al. Multiprovincial monitoring of the trends and determinants in cardiovascular diseases (Sino-Monica project): morbidity and mortality monitoring.
Chin J Cardiol
.
1997
;
25
:
6
–11

[31]

Jackson
R
, Barham P, Bills J, et al. Management of raised blood pressure in New Zealand: a discussion document.
BMJ
.
1993
;
307
:
107
–110

[32]

Guidelines Subcommittee. 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension.

J Hypertens
.
1999
;
17
:
151
–183

[33]

Tudor-Smith
C
, Nutbeam D, Moore L, Catford J. Effects of the Heartbeat Wales programme over five years on behavioral risks for cardiovascular disease: quasi-experimental comparison of results from Wales and a matched reference area.
BMJ
.
1998
;
316
:
818
–822

[34]

Puska
P
. The North Karelia Project: nearly 20 years of successful prevention of CVD in Finland.
Hygie
.
1992
;
11
:
33
–35

[35]

Farquhar
J
, Fortmann S, Flora J, et al. Effects of community wide education of cardiovascular risk factors: the Stanford five-city project.
JAMA
.
1990
;
264
:
359
–365

[36]

Luepker
R
, Murray D, Jacobs D, et al. Community education for cardiovascular disease prevention: risk factor changes in the Minnesota heart health program.
JAMA
.
1994
;
84
:
1383
–1393

[37]

Carleton
R
, Lasater T, Assaf A, Feldman H, McKinlay SPawtucket Heart Health Program Writing Group. The Pawtucket Heart Health Program: community changes in cardiovascular risk factors and projected disease risk.
Am J Public Health
.
1995
;
85
:
777
–785

[38]

Mullen
P
, Mains D, Velez R. A meta-analysis of controlled trials of cardiac education.
Patient Educ Couns
.
1992
;
19
:
143
–162

PDF
This content is only available as a PDF.
Topic:
Issue Section:
Articles
Download all slides